REMICADE: FDA Approves Second Biosimilar to Remicade

On April 21, 2017 FDA announced that it approved Renflexis (infliximab-abda) a biosimilar to Janssen Biotech s blockbuster Remicade (infliximab). This is the second approved biosimilar for Remicade Celltrion s Inflectra (infliximab-dyyb) was approved by the agency in early April 2016. Renflexis